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iNTRODUCTION
Follicular lymphoma (FL) is the second most
ommon lymphoma in the United States and Western
urope, comprising approximately 20% of all non-
odgkin lymphomas (NHLs) and up to 70% of the
ndolent lymphomas in Western countries. Although
he natural history of this disease has not changed
igniﬁcantly in the past 3 decades, newer agents, spe-
iﬁcally, antibody-based therapies, have changed the
pproach and may well alter the long-term outcome
or these patients.
Treatment options and the interpretation of clin-
cal studies need to be within the context of prognostic
actors. The current model used in FL is the Follicular
ymphoma International Prognostic Index, based on
n international study of long-term survival in 4167
atients with FL diagnosed between 1985 and 1992
1]. In this model, 5 adverse prognostic factors were
dentiﬁed: age 60 years; stage III or IV; hemoglobin
12 g/dL; number of involved nodal areas 4; and
erum lactate dehydrogenase (LDH) greater than the
pper limit of normal. With this model, 3 risk groups
ere identiﬁed—low (0 risk factors or 1 risk factor),
ntermediate (2 risk factors), and high (3 risk fac-
ors)—and the 10-year survivals for these risk groups
re 71%, 51%, and 36%, respectively. It is important
o note that this model predates the use of monoclonal
ntibody therapy, and the effect of these factors may
herefore change.
In 2005, there is evidence for the following con-
erning the treatment of FL: (1) early treatment in the
bsence of symptomatic disease or disease causing
rgan compromise does not affect survival; (2) com-
ination chemotherapy does not affect survival; (3)
urrently there is no survival beneﬁt of newer agents,
ncluding monoclonal antibodies (alone, with chemo- s
B&MTherapy, or radiolabeled) or purine analogues; and (4)
hemotherapy with rituximab or rituximab given as
aintenance delays relapse. However, in a disease
ith a long natural history, newer approaches are
ikely to need long follow-up for a survival effect to be
een.
HERAPY FOR EARLY-STAGE DISEASE
Only 10% to 25% of patients have clinical stage
/II disease, and far less than 10% have pathologic
tage I/II disease. Radiation therapy is the mainstay of
reatment for patients with limited-stage FL grade I or
I. The 10-year freedom from treatment failure in all
studies ranged from 41% to 49%. The 10-year
verall survival (all causes) ranged from 43% to 79%,
ith a median survival of 11.9 to 15.3 years [2].
The role of combination chemotherapy in the
anagement of early-stage FL is uncertain. At least 3
andomized studies conducted in the 1970s failed to
emonstrate that combination chemotherapy regi-
ens plus radiation therapy were superior to radiation
herapy alone. A 1994 study randomized patients to
eceive either radiation therapy alone or radiation
herapy plus chlorambucil, and there were no differ-
nces in freedom from recurrence or overall survival
etween the groups [3].
HERAPY OF PREVIOUSLY UNTREATED
DVANCED-STAGE DISEASE
Close observation is still a reasonable option for
symptomatic patients with low-volume disease. A
ritish National Lymphoma Investigation random-
zed study involving 309 patients with asymptomatic
tage III or IV indolent NHL reported no differences
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5n overall survival or cause-speciﬁc survival between
atients who were observed and those who received
mmediate treatment with chlorambucil [4]. The ac-
uarial chance of not requiring chemotherapy at 10
ears in the entire observation group was 19%, and it
as 40% and 16% for those older or younger than 70
ears, respectively.
onventional Chemotherapy
Indolent lymphomas are very sensitive to both
lkylating agents (eg, chlorambucil and cyclophosph-
mide) and combination chemotherapy; complete re-
ponse (CR) rates range from 30% to 60% for previ-
usly untreated patients [5]. However, the median
uration of CR with either a single alkylating agent
for example, cyclophosphamide) or combination che-
otherapy (for example, cyclophosphamide, vincris-
ine, and prednisone [CVP]) is only approximately 2.5
ears.
In an attempt to improve the relapse-free and
verall survival in patients with FL, more aggressive
ombination chemotherapy regimens have been used,
ith CR rates of 35% to 70%, but the median relapse-
ree survival remains similar to that seen with CVP, in
he range of 1.5 to 3 years. Cyclophosphamide, doxo-
ubicin, vincristine, prednisone (CHOP)-bleomycin
as compared with cyclophosphamide alone in pa-
ients with FL grade I and II, and the CR rate and
ime to failure were not statistically different between
he 2 arms for the entire patient population [6]. How-
ver, in the 46 patients with FL grade II, the failure-
ree and overall survival were better for combination
hemotherapy. Still, because of problems of reproduc-
bility of histologic interpretation of FL grade II and
he limited number of patients in this study, the use of
oxorubicin-containing regimens for patients with FL
emains controversial.
ombined-Modality Therapy
Studies from the National Cancer Institute and
tanford have failed to demonstrate an improved re-
apse-free or overall survival for patients treated with
VP with or without total body irradiation or total
ymphoid irradiation. The M.D. Anderson Cancer
enter reported an 81% CR rate, a 75% 5-year sur-
ival, and a 52% 5-year relapse-free survival for pa-
ients with stage III FL treated with CHOP-bleomy-
in and involved-ﬁeld radiotherapy [7].
urine Analogues
The purine analogues cladribine (2-chlorodeoxya-
enosine) and ﬂudarabine are active agents in FL.
ludarabine and cladribine have been effective agents
hen given as single agents in previously untreated
nd previously treated patients. In previously un-
reated patients with FL, the overall response rate to
4udarabine was 65%, with a 37% CR; the median
rogression-free survival (PFS) was 13.6 months [8].
imilar results were obtained with cladribine. Fludara-
ine was compared with CVP in a randomized study
f 381 patients with newly diagnosed advanced-stage
L. The overall response rates in the ﬂudarabine and
VP arms were 68% (38% CR) and 50% (15% CR).
igniﬁcant cytopenias were more frequent in the ﬂu-
arabine group. The median time to progression in the
udarabine group was 21 months, versus 15 months in
he CVP group. However, no differences in overall
urvival were detected [9].
Fludarabine has been combined with other che-
otherapeutic agents in previously untreated patients
ith indolent lymphoma. In a phase II multicenter
rial, the combination of cyclophosphamide, ﬂudara-
ine, and ﬁlgrastim resulted in overall response rates
f 92% in patients with previously untreated FL [10].
owever, when this combination was brought to the
ntergroup setting, signiﬁcant mortality from infec-
ion occurred, and the trial was closed early.
The combination of ﬂudarabine and mitoxantrone
as tested in previously untreated patients with indolent
ymphoma (FL and small lymphocytic lymphoma) [11].
verall and CR rates were 91% and 43%, respectively,
ith 2-year PFS and overall survival rates of 63% and
3%, respectively. The addition of dexamethasone to
udarabine/mitoxantrone has been shown to be a highly
ffective regimen for patients with relapsed indolent
ymphomas, with overall response and CR rates of
4% and 47%, respectively. The median failure-free
urvival was 14 months for all patients and 21 months
or those who attained CR.
onoclonal Antibody Therapy
Anti–B-cell monoclonal antibody therapy has changed
he treatment options for patients with FL. On the
asis of the activity of rituximab as a single agent in
atients with relapsed FL, several phase II trials have
sed rituximab initial therapy in patients with indolent
ymphoma [12,13]. In 62 chemotherapy-naive pa-
ients, most of whom had stage III or IV disease,
verall response rates at 6 weeks and at maximum
esponse were 47% and 73%, with 7% and 37% CRs,
espectively [12,14]. At a median follow-up of 30
onths, the median PFS was 34 months. A second
rial evaluated 50 patients with stage II to IV FL and
low tumor burden (no nodal or extranodal mass 7
m, “B” symptoms, splenomegaly, pleural effusion,
scites, organ compression, increased serum LDH, or
2-microglobulin) [13]. The overall response rate at
0 days was 73%, with 57% and 31% of informative
atients negative by polymerase chain reaction (PCR)
or bcl-2 rearrangement in peripheral blood and bone
arrow, respectively.
A recent trial by Witzig et al. [15] reported 37
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Batients with FL grade I treated with 4 weekly doses of
ituximab, with an overall response rate of 72% and
6% CRs. The median time to progression was 2.2
ears, and they noted that patients with increased
DH had a response rate of 33% and a median time
o progression of only 6 months.
The role of maintenance therapy with rituximab
emains uncertain. A study of 62 patients, 38 with FL,
valuated a course of standard rituximab followed by 4
ourses every 6 months [14]. The ﬁnal response rate
as 73%, with 37% CRs, and the median PFS was 34
onths. This suggests that additional doses of ritux-
mab increased the response rate and the duration of
esponse. A randomized trial compared prolonged rit-
ximab (375 mg/m2) every 2 months  4 doses with
o maintenance in patients whose disease was re-
ponding or stable after the standard 4 doses of ritux-
mab [16]. A signiﬁcant prolongation of event-free
urvival was observed with extended dosing. These
tudies demonstrate that rituximab is a very active
gent, but its effect on survival has not been demon-
trated to date.
ituximab Plus Chemotherapy
Rituximab has been combined with CHOP che-
otherapy, with encouraging results in patients with
ndolent lymphoma: overall response and CR rates
ere 100% and 63%, respectively [17]. The South-
est Oncology Group has conducted a study of ritux-
mab after CHOP chemotherapy for the treatment of
ewly diagnosed FL [18]. The overall response rate
as 72%, and rituximab converted 14 partial remis-
ions to CRs. The 2-year PFS in this study was 76%.
n a single-center open-label phase II trial in 40 pa-
ients, 27 of whom were treatment naive, the combi-
ation of ﬂudarabine and rituximab achieved an over-
ll response rate of 90% (CR rate, 80%) [19]. In the 16
ubjects positive for t(14;18) at enrollment, molecular
emission was attained in 88%. Serial PCR assays have
emained negative for up to 4 years in those who
ttained molecular remission. At a median follow-up
f 44 months, the median duration of response, time
o progression, and overall survival had not been
eached.
An international multicenter randomized trial of
21 patients with previously untreated stage III/IV FL
ompared 8 cycles of CVP or 8 cycles of CVP plus
ituximab [20]. Overall (81% versus 57%) and com-
lete (41% versus 10%) response rates were higher in
he CVP-rituximab treatment arm. At a median fol-
ow-up of 30 months, the median times to progression
32 versus 15 months) and treatment failure (27 versus
months) were signiﬁcantly longer in the CVP-rit-
ximab arm. However, no survival advantage for
VP-rituximab has been noted to date (89% versus
5% survival at 30 months). b
B&MTadioimmunoconjugates
Two anti-CD20 radioimmunoconjugates have been
pproved for the treatment of indolent lymphomas. Ka-
inski et al. [21] reported that a single course of
reatment with iodine 131 (131I)–tositumomab, given
o 76 previously untreated patients with FL, had over-
ll and CR rates of 95% and 75%, respectively, and
-year overall survival and PFS of 89% and 59%,
espectively. Five-year PFS was 77% for those who
ttained CR, whereas all patients who achieved partial
emission had disease progression at a median time of
months. Of the 39 patients whose baseline bone
arrows were PCR positive for t(14;18), 34 (87%)
ecame PCR negative after B-cell recovery at 6
onths. In a phase II study of CHOP followed by
31I-tositumomab conducted by the Southwest Oncol-
gy Group in patients newly diagnosed with FL, the
verall response rate was 80%, including 50% CRs
22]. The role of up-front use of 131I-tositumomab in
L patients is currently being examined in a random-
zed trial comparing CHOP followed by rituximab
ith CHOP followed by 131I-tositumomab.
nterferon
Prospective randomized trials have examined the
se of interferon along with combination chemother-
py in patients with advanced-stage disease [23].
hese studies have generally reported a signiﬁcant
mprovement in PFS. Two trials that involved main-
enance interferon alfa had a signiﬁcant prolongation
f survival. A phase III trial compared interferon
lfa-2b with observation after induction therapy with
ggressive combination chemotherapy for previously
ntreated patients with indolent NHL, and no signif-
cant difference in PFS or overall survival was found
etween the 2 groups [24]. Given the variability of
esults of the various trials, the expense and toxicity of
reatment, and the lack of trials in which interferon
as used along with rituximab and other newer treat-
ent regimens, the use of interferon after intensive
hemotherapy does not seem warranted.
HERAPY OF RECURRENT FOLLICULAR NHL
In general, only 20% to 25% of patients are dis-
ase free at 4 years after conventional chemotherapy
n the prerituximab era. After relapse, these diseases
ontinue to be sensitive to single alkylating agents and
VP, but the median relapse-free survival progres-
ively decreases with each subsequent relapse.
Purine analogues are very active agents in patients
ith relapsed and refractory disease. The overall re-
ponse rate of previously treated patients with FL to
udarabine ranged from 48% to 100%, with a CR rate
f 20%. A randomized trial has compared ﬂudara-
ine with CVP in previously treated patients with FL.
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5lthough the response rates (62% versus 52%) and
-year overall survival (70% versus 75%) seemed sim-
lar, the 2-year PFS was signiﬁcantly improved with
udarabine (32% versus 14%; P  .03) [25].
The pivotal trial of the anti-CD20 monoclonal
ntibody rituximab in patients with relapsed or refrac-
ory follicular or low-grade lymphoma showed an
verall response rate of 48% [26]. There were CRs in
% of patients, and the subset of patients with FL had
response rate of 59%. The median time to progres-
ion in this study was 9 to 11 months. A phase II trial
tudied re-treatment with rituximab in 57 patients
ith relapsed, advanced, indolent lymphoma (small
ymphocytic lymphoma and predominantly FL), all of
hom had previously responded to treatment with
his agent in 1 or more trials [27]. The overall re-
ponse rate was 40%, with 11% CRs; the estimated
edian time to progression after treatment was 18
onths.
Rituximab has been combined with chemother-
py, with high response rates and longer remissions.
HOP plus rituximab has been reported in 9 patients
ith prior treatment, and 7 patients have either a CR
r an unconﬁrmed CR, with a median PFS of 48
onths [17]. Fludarabine and rituximab have been
ombined in a phase II trial of 40 patients, including
3 previously treated patients (most with FL). The
verall response rate was 92% in these 13 patients,
nd 77% had a CR [19]. The German Low Grade
ymphoma Study Group has reported a randomized
rial in patients with relapsed or refractory FL (and
antle cell lymphoma) [28]. Patients received 4 cycles
f ﬂudarabine, cyclophosphamide, and mitoxantrone
FCM) with or without rituximab. The overall and CR
ates were higher for FCM-rituximab than FCM (79
ersus 58% and 33 versus 13%). FCM-rituximab also
igniﬁcantly improved relapse-free survival.
Ibritumomab tiuxetan is composed of the murine
nti-CD20 monoclonal antibody ibritumomab co-
alently bonded to the linker chelator tiuxetan, radio-
abeled with yttrium 90 for therapy and indium 111
or imaging, dosimetry, or both. In a phase III study,
43 patients with relapsed or refractory low-grade,
ollicular, or transformed CD20 lymphoma were
andomized to receive either rituximab or ibritu-
omab tiuxetan [29]. The overall response rates to
ituximab and ibritumomab tiuxetan were 56% and
0%, respectively (P .002). Interim results indicated
hat the response rates to the ibritumomab tiuxetan
ombination were similar in the chemorefractory
77%) and chemosensitive (81%) patients. In a study
f rituximab-refractory patients, the overall response
ate was 74%. The estimated median duration of re-
ponse after ibritumomab tiuxetan therapy (7.7
onths) was longer than that after prior rituximab
herapy (4.0 months) and prior chemotherapy (6.5
onths). p
6Tositumomab is a murine anti-CD20 monoclonal
ntibody conjugated with radioactive 131I tositu-
omab. In a study of 60 patients with previously
reated or resistant low-grade or transformed low-
rade NHL, an overall response rate of 65% (20%
R) was observed [30]. The median duration of re-
ission had not been reached by 47 months. In a
hase III study comparing unlabeled tositumomab
ith 131I tositumomab, 17% of patients responded to
he unlabeled murine antibody, and 55% of patients
eceiving 131I tositumomab responded [31]. Seventeen
f 19 nonresponders in the unlabeled arm crossed
ver to 131I tositumomab and subsequently responded.
n a review of 995 patients treated with 131I tositu-
omab, the incidence of treatment-related myelodys-
lastic syndrome or acute myelogenous leukemia was
.5% [32]. Further follow-up is needed to deﬁne the
verall risk of this disorder; however, patients with
bnormal bone marrow cytogenetics or clonal hema-
opoiesis should probably avoid radioimmunotherapy.
UTURE DIRECTIONS
mproving Monoclonal Antibody Therapy
Augmenting antibody-dependent cell-mediated cy-
otoxicity may improve the response rates and response
uration of single-agent rituximab. Several investiga-
ors have explored combination immunotherapy with
ituximab and immunostimulants such as interleukin
, interleukin 12, and interferon alfa [33]. These stud-
es suggest such combinations are safe and may pro-
ong PFS. Several other novel monoclonal antibodies
ith activity against B-cell lymphoma are being eval-
ated, including epratuzumab (anti-CD22) [34] and
aliximab (anti-CD80) [35]. In early studies, these
ntibodies have demonstrated efﬁcacy and tolerability
n patients with relapsed FL. Clinical trials are ongo-
ng to evaluate these antibodies as single agents and in
ombination with rituximab.
nti–bcl-2 Therapy
An obvious target in FL is the bcl-2 gene, which is
verexpressed in 85% of patients with FL and t(14;
8). In phase I trials of bcl-2 antisense, a limited
umber of responses have been obtained, even in the
resence of advanced or relapsed disease [36]. Several
ther small molecules that target BCL-2 are in early-
hase trials.
accines
Several approaches of vaccination have been used
n clinical trials of patients with FL, and the most
requent target is the idiotype. In phase II studies,
nti-idiotype immune responses occurred after vacci-
ation in approximately 50% of patients, and these
atients had prolonged PFS compared with historical
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Bontrols [37]. Currently, there are 3 randomized trials
valuating the role of idiotype vaccination after che-
otherapy or rituximab in patients with previously
ntreated FL. Ongoing and future studies in these
reas may provide novel alternatives and complement
onventional therapy.
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